Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0124 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0098 | 0.7014 | 0.5379 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0098 | 0.7014 | 0.7014 |
Loa Loa (eye worm) | hypothetical protein | 0.0098 | 0.7014 | 0.5379 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0067 | 0.3539 | 0.3539 |
Echinococcus multilocularis | tar DNA binding protein | 0.0124 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0124 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0124 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0124 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0067 | 0.3539 | 0.3539 |
Brugia malayi | TAR-binding protein | 0.0124 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0124 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0124 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0098 | 0.7014 | 0.7014 |
Loa Loa (eye worm) | RNA binding protein | 0.0124 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0124 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0124 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0124 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (binding) | = 20.948 uM | PUBCHEM_BIOASSAY: HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488787] | ChEMBL. | No reference |
Potency (functional) | 0.2936 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 30.1313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | = 100 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.